• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

髓系低氧诱导因子 2α 对于维持全身铁稳态并非必需。

Myeloid Hif2α is not essential to maintain systemic iron homeostasis.

机构信息

Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI.

Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI; Department of Cellular and Molecular Biology, University of Michigan, Ann Arbor, MI; Department of Medical Scientist Training Program, University of Michigan, Ann Arbor, MI.

出版信息

Exp Hematol. 2023 Sep-Oct;125-126:25-36.e1. doi: 10.1016/j.exphem.2023.08.001. Epub 2023 Aug 8.

DOI:10.1016/j.exphem.2023.08.001
PMID:37562670
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11046397/
Abstract

Dietary consumption serves as the primary source of iron uptake, and erythropoiesis acts as a major regulator of systemic iron demand. In addition to intestinal iron absorption, macrophages play a crucial role in recycling iron from senescent red blood cells. The kidneys are responsible for the production of erythropoietin (Epo), which stimulates erythropoiesis, whereas the liver plays a central role in producing the iron-regulatory hormone hepcidin. The transcriptional regulator hypoxia-inducible factor (HIF)2α has a central role in the regulation of Epo, hepcidin, and intestinal iron absorption and therefore plays a crucial role in coordinating the tissue crosstalk to maintain systemic iron demands. However, the precise involvement of Hif2α in macrophages in terms of iron homeostasis remains uncertain. Our study demonstrates that deleting Hif2α in macrophages does not disrupt the expression of iron transporters or basal erythropoiesis. Mice lacking Hif2α in myeloid cells exhibited no discernible differences in hemodynamic parameters, including hemoglobin concentrations and erythrocyte count, when compared with littermate controls. This similarity was observed under conditions of both dietary iron deficiency and acute erythropoietic demand. Notably, we observed a significant increase in the expression of iron transporters in the duodenum during iron deficiency, indicating heightened iron absorption. Therefore, our findings suggest that the disruption of Hif2α in myeloid cells does not significantly impact systemic iron homeostasis under normal physiologic conditions. However, its disruption induces adaptive physiologic changes in response to elevated iron demand, potentially serving as a mechanism to sustain increased erythropoietic demand.

摘要

饮食摄入是铁吸收的主要来源,而红细胞生成是调节全身铁需求的主要因素。除了肠道铁吸收外,巨噬细胞在从衰老的红细胞中回收铁方面起着至关重要的作用。肾脏负责产生促红细胞生成素(Epo),刺激红细胞生成,而肝脏在产生铁调节激素hepcidin方面起着核心作用。转录调节因子缺氧诱导因子(HIF)2α在调节 Epo、hepcidin 和肠道铁吸收方面起着核心作用,因此在协调组织串扰以维持全身铁需求方面起着至关重要的作用。然而,Hif2α 在巨噬细胞中对铁平衡的确切参与仍不确定。我们的研究表明,巨噬细胞中 Hif2α 的缺失不会破坏铁转运蛋白或基础红细胞生成的表达。与同窝对照相比,骨髓细胞中缺乏 Hif2α 的小鼠在血流动力学参数(包括血红蛋白浓度和红细胞计数)方面没有明显差异。在饮食缺铁和急性红细胞生成需求的情况下,都观察到了这种相似性。值得注意的是,我们观察到在缺铁期间十二指肠中铁转运蛋白的表达显著增加,表明铁吸收增加。因此,我们的研究结果表明,在正常生理条件下,骨髓细胞中 Hif2α 的缺失不会显著影响全身铁平衡。然而,它的缺失会诱导对升高的铁需求的适应性生理变化,可能作为维持增加的红细胞生成需求的一种机制。

相似文献

1
Myeloid Hif2α is not essential to maintain systemic iron homeostasis.髓系低氧诱导因子 2α 对于维持全身铁稳态并非必需。
Exp Hematol. 2023 Sep-Oct;125-126:25-36.e1. doi: 10.1016/j.exphem.2023.08.001. Epub 2023 Aug 8.
2
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.欧洲癌症研究与治疗组织(EORTC)癌症贫血患者促红细胞生成蛋白使用指南:2006年更新版
Eur J Cancer. 2007 Jan;43(2):258-70. doi: 10.1016/j.ejca.2006.10.014. Epub 2006 Dec 19.
3
A bulge uridine in the HIF2α IRE allows IRP1 but not IRP2 to selectively regulate HIF2α expression and ensuing EPO levels.缺氧诱导因子2α(HIF2α)铁反应元件(IRE)中的一个凸起尿苷使得铁调节蛋白1(IRP1)而非铁调节蛋白2(IRP2)能够选择性地调控HIF2α的表达及随后的促红细胞生成素(EPO)水平。
Blood. 2025 Jan 30;145(5):533-542. doi: 10.1182/blood.2024025246.
4
Hepcidin: A multifaceted hormone in iron homeostasis and tumor biology.铁调素:铁稳态和肿瘤生物学中的一种多面性激素。
Vitam Horm. 2025;129:317-360. doi: 10.1016/bs.vh.2024.10.003. Epub 2024 Oct 24.
5
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
6
Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).促红细胞生成素和低氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHDi)可降低慢性肾脏病(CKD)模型中的 FGF23。
Physiol Rep. 2020 Jun;8(11):e14434. doi: 10.14814/phy2.14434.
7
Treatment for women with postpartum iron deficiency anaemia.产后缺铁性贫血女性的治疗。
Cochrane Database Syst Rev. 2015 Aug 13;2015(8):CD010861. doi: 10.1002/14651858.CD010861.pub2.
8
Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review.铁调素:铁紊乱的一个有前景的治疗靶点:一项系统评价
Medicine (Baltimore). 2016 Apr;95(14):e3150. doi: 10.1097/MD.0000000000003150.
9
Treatment for women with postpartum iron deficiency anaemia.产后缺铁性贫血女性的治疗。
Cochrane Database Syst Rev. 2024 Dec 13;12(12):CD010861. doi: 10.1002/14651858.CD010861.pub3.
10
The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.在小鼠中,缺氧诱导因子脯氨酰羟化酶抑制剂的药物特异性表明,与肝脏相比,肾脏对红细胞生成素的诱导有重要贡献。
Life Sci. 2024 Jun 1;346:122641. doi: 10.1016/j.lfs.2024.122641. Epub 2024 Apr 15.

本文引用的文献

1
The mutual crosstalk between iron and erythropoiesis.铁与红细胞生成的相互作用。
Int J Hematol. 2022 Aug;116(2):182-191. doi: 10.1007/s12185-022-03384-y. Epub 2022 May 27.
2
Modulation of the HIF2α-NCOA4 axis in enterocytes attenuates iron loading in a mouse model of hemochromatosis.肠细胞中 HIF2α-NCOA4 轴的调节可减轻血色病小鼠模型中的铁负荷。
Blood. 2022 Apr 21;139(16):2547-2552. doi: 10.1182/blood.2021013452.
3
Hepcidin sequesters iron to sustain nucleotide metabolism and mitochondrial function in colorectal cancer epithelial cells.
亚铁整合素通过螯合铁来维持结直肠癌细胞上皮细胞中的核苷酸代谢和线粒体功能。
Nat Metab. 2021 Jul;3(7):969-982. doi: 10.1038/s42255-021-00406-7. Epub 2021 Jun 21.
4
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.罗沙司他治疗长期透析患者的贫血。
N Engl J Med. 2019 Sep 12;381(11):1011-1022. doi: 10.1056/NEJMoa1901713. Epub 2019 Jul 24.
5
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.罗沙司他治疗未透析的日本慢性肾脏病相关贫血患者的疗效:一项 2 期、随机、双盲、安慰剂对照试验。
Adv Ther. 2019 Jun;36(6):1438-1454. doi: 10.1007/s12325-019-00943-4. Epub 2019 Apr 5.
6
Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload.肝脏铁调素/肠道 HIF-2α 轴在缺铁和铁过载期间维持铁吸收。
J Clin Invest. 2019 Jan 2;129(1):336-348. doi: 10.1172/JCI122359. Epub 2018 Dec 10.
7
Haemochromatosis.血色病。
Nat Rev Dis Primers. 2018 Apr 5;4:18016. doi: 10.1038/nrdp.2018.16.
8
Targeting renal cell carcinoma with a HIF-2 antagonist.用低氧诱导因子-2拮抗剂靶向治疗肾细胞癌。
Nature. 2016 Nov 3;539(7627):112-117. doi: 10.1038/nature19796. Epub 2016 Sep 5.
9
Ironing out Ferroportin.解决铁转运蛋白问题
Cell Metab. 2015 Nov 3;22(5):777-87. doi: 10.1016/j.cmet.2015.09.006. Epub 2015 Oct 1.
10
Intestine-specific Disruption of Hypoxia-inducible Factor (HIF)-2α Improves Anemia in Sickle Cell Disease.肠道特异性破坏缺氧诱导因子(HIF)-2α可改善镰状细胞病的贫血症状。
J Biol Chem. 2015 Sep 25;290(39):23523-7. doi: 10.1074/jbc.C115.681643. Epub 2015 Aug 19.